Despite the high prevalence of LPR, socioeconomic cost and burden on quality of life, there is currently no effective medical therapy. Pepsin, detected in the airway of patients with LPR and now known to cause inflammation and promote disease independent of gastric acid, is a key therapeutic target. Our cutting-edge research demonstrates fosamprenavir binds to and inhibits pepsin, preventing pepsin-mediated inflammation and tissue damage. N-Zyme is developing a sustained-release oral formulation of fosamprenavir for the treatment of reflux. Furthermore, an innovative delivery approach will provide local delivery of a low dose of fosamprenavir direct to the throat. These oral and dry powder inhaler medications will be the first safe, effective, and efficient treatments for the millions of people that suffer from LPR, addressing a significant unmet clinical need.
» What is LPR?Therapeutic area: Reflux
Phase: III
Program: NZYM-001 (Oral suspension pepsin inhibitor)
Indication: Laryngopharyngeal Reflux (LPR)
Therapeutic area: Reflux
Phase: Preclinical
Program: NZYM-002 (Inhaled pepsin inhibitor)
Indication: Laryngopharyngeal Reflux (LPR)
U.S. Patent Application No. 63/392,929
Filed July 28, 2022
Sustained-release oral Fosamprenavir for the treatment of reflux
Inventors: Nikki Johnston and Franco Gennaro Vigile
Applicants: The Medical College of Wisconsin, Inc. and N-Zyme Biomedical Inc.
International Patent Application: PCT/US2021/027758
FILED April 16, 2021
Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
Inventors: Nikki Johnston
Applicants: The Medical College of Wisconsin, Inc.
Our new, sustained-release oral fosamprenavir formulation contains sodium alginate to increase muco-adhesion and prolong esophageal retention and contact time. Local esophageal delivery of a pepsin inhibitor such as fosamprenavir is expected to benefit to the ~50% of LPR patients that have GERD.
This award comes with a grant that will go towards the drug reformulation process.
Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.